XML 36 R22.htm IDEA: XBRL DOCUMENT
v3.20.2

Equity - contributed equity | 12 Months Ended
--- | ---
Jun. 30, 2020
Text block [abstract] |
Equity - contributed equity | Note 18. Equity - contributed equity
|  | Consolidated |
|  | 2020 Shares |  |  | 2019 Shares |  |  | 2020 $ |  |  | 2019 $ |
Ordinary shares - fully paid |  |  | 94,598,369 |  |  |  | 62,166,673 |  |  |  | 48,781,214 |  |  |  | 36,641,519 |
Movements in Ordinary share capital
Details |  | Date |  | Shares |  |  | Issue price |  |  | $ |
Balance |  | 1 July 2018 |  |  | 48,409,621 |  |  |  |  |  |  |  | 31,575,824 |
Share placement |  | 24 October 2018 |  |  | 8,900,001 |  |  | $ | 0.380 |  |  |  | 3,382,000 |
Milestone 1 shares issued in connection with purchase of Glioblast Pty Limited (GDC-0084) |  | 9 November 2018 |  |  | 2,820,824 |  |  | $ | 0.440 |  |  |  | 1,250,000 |
Issued under Share Purchase Plan |  | 23 November 2018 |  |  | 2,036,227 |  |  | $ | 0.380 |  |  |  | 773,760 |
Share issue transaction costs |  |  |  |  | — |  |  | $ | 0.000 |  |  |  | (340,065 | )
Balance |  | 30 June 2019 |  |  | 62,166,673 |  |  |  |  |  |  |  | 36,641,519 |
Share placement |  | 1 November 2019 |  |  | 10,000,000 |  |  | $ | 0.400 |  |  |  | 4,000,000 |
Share placement |  | 16 April 2020 |  |  | 18,041,667 |  |  | $ | 0.400 |  |  |  | 7,216,667 |
Issued under the Share Purchase Plan |  | 11 May 2020 |  |  | 4,390,010 |  |  | $ | 0.400 |  |  |  | 1,756,004 |
Issued on conversion of options |  |  |  |  | 19 |  |  | $ | 4.000 |  |  |  | 76 |
Share issue transaction costs |  |  |  |  | — |  |  | $ | 0.000 |  |  |  | (833,052 | )
Balance |  | 30 June 2020 |  |  | 94,598,369 |  |  |  |  |  |  |  | 48,781,214 |
Ordinary shares Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital. On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. Share buy-back There is no current on-market share buy-back. Capital risk management The consolidated entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. The capital structure of the consolidated entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the consolidated entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. The capital risk management policy remains unchanged from the prior year.

X
- Definition The disclosure of issued capital. [Refer: Issued capital] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_10_e&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfIssuedCapitalExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block [abstract] + References No definition available. + Details
Name: | kzia_TextBlockAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration